AbbVie Inc. ROIC

ROIC of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2019 was 43.55% (a 159.84% increase from previous year)
  • Annual ROIC for 2018 was 16.76% (a -8.21% decrease from previous year)
  • Annual ROIC for 2017 was 18.26% (a 9.67% increase from previous year)
  • Twelve month ROIC ending March 30, 2020 was 45.89% (a 5.37% increase compared to previous quarter)
  • Twelve month trailing ROIC increased by 139.76% year-over-year
Trailing ROIC for the last four month:
30 Mar '20 30 Dec '19 29 Sep '19 29 Jun '19
45.89% 43.55% 21.08% 19.14%
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of AbbVie Inc.

Most recent ROICof ABBV including historical data for past 10 years.

Interactive Chart of ROIC of AbbVie Inc.

AbbVie Inc. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 43.55%
2018 16.76%
2017 18.26%
2016 16.65%
2015 17.31%
2014 25.55%
2013 37.98%
2012 32.87%
2011 19.97%
2010 18.79%
2009 0.0%

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.